The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:

1. Effects of Combining Coronary Calcium Score With Treatment on Plaque
Progression in Familial Coronary Artery Disease A Randomized Clinical Trial JAMA 2025. Discussion by:
Guest:
Michael J. Blaha, MD, MPH
Professor of Cardiology and Epidemiology and presently serves as the
Director of Clinical Research for the Johns Hopkins Ciccarone Center for the
Prevention of Cardiovascular Disease
Director of the Cardiometabolic Clinic
Program Director for the Preventive Cardiology Fellowship.

2. Creatine monohydrate pilot in Alzheimer’s: Feasibility, brain creatine, and cognition. Alzheimer’s Dement. 2025. Discussion by:
Guest:
Michael Devano, DO
Attending Family Physician
Christiana Care Health System

3. Structured Exercise after Adjuvant Chemotherapy for Colon Cancer. The New England Journal of Medicine. Discussion by:
Guest:
Joseph Gonnella, MD
Resident– Family Medicine
Residency Program, Jefferson Health – Abington

Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.

This Podcast Episode does not offer CME/CE Credit.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/answers-in-chronic-spontaneous-urticaria-10190

Summary
In this short CE/CME activity, moderator Dr. Brad Glick works with dermatology expert Dr. Gil Yosipovitch to answer your top questions regarding chronic spontaneous urticaria, as gathered from the 2025 NACE Conversations in Dermatology symposium. Questions cover diagnosis, treatment individualization, and more!

Learning Objectives
At the conclusion of this activity, participants should be better able to:

• Assess the disease burden and impact on QoL in patients with CSU
• Evaluate current and emerging therapies for CSU

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This activity is supported by an independent educational grant from Sanofi and Regeneron Pharmaceuticals.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/copd-inflammation-exacerbations-your-questions-answered-10143

Summary
Rejoin the conversation on COPD, inflammation, and new and emerging agents as two of our expert faculty come together to answer your top questions. Questions submitted from the recent Conversations in Primary Care live virtual symposia guide the discussion as we dig a bit deeper on type 2 inflammation, changes in COPD management, and new and emerging agents – including recently approved biologic agents – for COPD.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

• Review the relationship between inflammation, exacerbation, and disease progression in COPD, noting different inflammatory endotypes of patients with COPD
• Discuss recent evidence surrounding the use of biologic agents in the management of patients with COPD and type 2 inflammation
• Integrate current guidelines with clinical data on new and emerging agents for the management of COPD, distinguishing patients with and without markers of type 2 inflammation

This activity is accredited for CME/CE Credit
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

The NACE Journal Club with Dr. Neil Skolnik, provides review and analysis of recently published journal articles important to the practice of primary care medicine. In this episode Dr. Skolnik and guests review the following publications:

1. Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) - New England Journal of Medicine 2025. Discussion by:
Guest:
Steven E. Nissen, M.D.,
 Chief Academic Officer of the Heart and Vascular Institute at the Cleveland Clinic
Professor of Medicine at the Lerner College of Medicine

2. Genitourinary Syndrome of Menopause: AUA/SUFU/AUGS Guideline (2025).
Discussion by: Discussion by:
Guest:
Anupriya Grover-Wenk, DO
Faculty– Family Medicine Residency Program
Jefferson Health – Abington

3. Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial. Discussion by:
Guest:
Joseph Gonnella, MD
Resident– Family Medicine Residency Program
Jefferson Health – Abington

Medical Director and Host, Neil Skolnik, MD, is an academic family physician who sees patients and teaches residents and medical students as professor of Family and Community Medicine at the Sidney Kimmel Medical College, Thomas Jefferson University and Associate Director, Family Medicine Residency Program at Abington Jefferson Health in Pennsylvania. Dr. Skolnik graduated from Emory University School of Medicine in Atlanta, Georgia, and did his residency training at Thomas Jefferson University Hospital in Philadelphia, PA.

This Podcast Episode does not offer CME/CE Credit.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/clinical-updates-in-schizophrenia-10097

Summary
In this PsychTalk podcast/webcast episode, Drs. Gregory Mattingly and Lisa Harding go through the evolving landscape of schizophrenia treatments. Listen as they discuss the pros and cons of various second-generation antipsychotics, the science behind muscarinic modulation for psychosis, and recent updates in clozapine prescribing. At the end of the session, the doctors answer several audience questions to enhance your understanding of these developments and how they apply to clinical practice.

This podcast was recorded and is being used with permission of the presenters.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

• Integrate recent clinical data on antipsychotic treatments and relapse prevention strategies into management plans for patients with schizophrenia
• Describe the role of muscarinic modulation in psychosis

This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.75 contact hours (which includes 0.75 hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This educational activity is not commercially supported.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:
https://www.mycme.com/courses/psychiatric-therapeutics-in-a-digital-world-10096

Summary
In this PsychTalk podcast/webcast episode, Drs. Gregory Mattingly and Lisa Harding delve into the digital world and breakdown its effects on mental health—both positive and negative. By the end of the episode, learners will have a better understanding of the relationship between screen time, social media, and attention, including clinical pearls for how to harness prescription technology to enhance patient outcomes in ADHD and depression.

This podcast was recorded and is being used with permission of the presenters.

Learning Objectives
At the conclusion of this activity, participants should be better able to:

• Examine the relationship between social media and attention
• Incorporate FDA-authorized digital therapeutics into ADHD and depression management plans based on current clinical evidence

This activity is accredited for CME/CE Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the ACCME to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners® (AANP) through the joint providership of the National Association for Continuing Education (NACE) and GlobalHealthXchange. NACE is accredited by the AANP as an approved provider of nurse practitioner continuing education. Provider number 121222. This activity is approved for 0.50 contact hours (which does not include hours of pharmacology).

For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.

Summary of Individual Disclosures
Please review faculty and planner disclosures here.

Disclosure of Commercial Support
This educational activity is not commercially supported.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Please visit http://naceonline.com to engage in more live and on demand CME/CE content.